Tokai Pharmaceuticals, Inc. (NASDAQ:NVUS) posted its earnings results on Wednesday. The biopharmaceutical company reported ($0.43) EPS for the quarter, Bloomberg Earnings reports.

Tokai Pharmaceuticals (NVUS) traded up $0.01 during trading hours on Friday, hitting $3.81. 7,117 shares of the stock traded hands, compared to its average volume of 20,912. The company has a quick ratio of 7.86, a current ratio of 7.86 and a debt-to-equity ratio of 0.01. Tokai Pharmaceuticals has a one year low of $3.42 and a one year high of $15.12.

WARNING: “Tokai Pharmaceuticals, Inc. (NVUS) Posts Quarterly Earnings Results” was first posted by Watch List News and is owned by of Watch List News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at

An institutional investor recently bought a new position in Tokai Pharmaceuticals stock. Vanguard Group Inc. bought a new position in shares of Tokai Pharmaceuticals, Inc. (NASDAQ:NVUS) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 42,803 shares of the biopharmaceutical company’s stock, valued at approximately $251,000. Vanguard Group Inc. owned approximately 5.78% of Tokai Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 39.76% of the company’s stock.

Tokai Pharmaceuticals Company Profile

Novus Therapeutics, Inc, formerly Tokai Pharmaceuticals, Inc, is a pharmaceutical company. The Company is focused on the acquisition, development, and commercialization of ear, nose, and throat products. It has two platforms: OP-01 Foam Platform and OP-02 Surfactant Program. OP-01 is developed with the intent to be used as a delivery vehicle for drugs treating ears, as well as the nasal and sinus cavities.

Earnings History for Tokai Pharmaceuticals (NASDAQ:NVUS)

Receive News & Ratings for Tokai Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tokai Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.